Physician profile
Michael A Ramos
NPI 1699743724
$2,604.53
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $580 · 2021: $548 · 2022: $277 · 2023: $717 · 2024: $99.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.81 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $301.77 | 2020-2023 | |
| Astellas Pharma US INC | $232.81 | 2023 | Veozah, Myrbetriq |
| Pfizer INC. | $168.55 | 2021-2024 | |
| Lilly USA, LLC | $161.99 | 2019-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $147.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.34 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.39 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $86.67 | 2019-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $81.23 | 2021 | |
| Glaxosmithkline, LLC. | $79.50 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $61.32 | 2022-2023 | Quviviq |
| Dexcom, INC. | $46.93 | 2021-2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $46.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.96 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.30 | 2020 | |
| Amgen INC. | $27.89 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.44 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.45 | 2022 | |
| Inogen, INC. | $22.41 | 2022 | |
| Therapeuticsmd, INC. | $20.72 | 2019 | |
| Grifols USA, LLC | $20.55 | 2019 | |
| Eisai INC. | $20.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.33 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.19 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.72 | 2021 | |
| Lupin INC. | $15.21 | 2019 | |
| Alkermes, INC. | $11.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.